CCR5Δ32 59537-G/A promoter polymorphism is associated with low translational efficiency and the loss of CCR5Δ32 protective effects

Journal of Virology

Volumn 82, Issue 5, 2008, Pages 2418-2426

  Jin, Qingwen ^a,d   Agrawal, Lokesh ^a   Meyer, L ^b   Tubiana, R ^c   Theodorou, Ioannis ^c   Alkhatib, Ghalib ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BICÊTRE HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; MESSENGER RNA;

ARTICLE; CELL SURFACE; COMPARATIVE STUDY; CONTROLLED STUDY; EMBRYO; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RNA TRANSLATION; SAMPLE; TRANSLATION REGULATION; 5' UNTRANSLATED REGION; GENETICS; HELA CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

HUMAN IMMUNODEFICIENCY VIRUS;

5' UNTRANSLATED REGIONS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HELA CELLS; HIV INFECTIONS; HUMANS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROTEIN BIOSYNTHESIS; RECEPTORS, CCR5; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 39749084581     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01596-07     Document Type: Article

References (42)

1. Agrawal, L., Q. Jin, J. Altenburg, L. Meyer, R. Tubiana, I. Theodorou, and G. Alkhatib. 2007. CCR5Δ32 protein expression and stability are critical for resistance to HIV-1 in vivo. J. Virol. 81:8041-8049.
2. + cells. J. Virol. 78:2277-2287.
3. Alkhatib, G., C. C. Broder, and E. A. Berger. 1996. Cell type-specific fusion cofactors determine human immunodeficiency virus type 1 tropism for T-cell lines versus primary macrophages. J. Virol. 70:5487-5494.
4. Alkhatib, G., C. Combadiere, C. C. Broder, Y. Feng, P. E. Kennedy, P. M. Murphy, and E. A. Berger. 1996. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955-1958.
5. Balotta, C., P. Bagnarelli, M. Violin, A. L. Ridolfo, D. Zhou, A. Berlusconi, S. Corvasce, M. Corbellino, M. Clementi, M. Clerici, M. Moroni, and M. Galli. 1997. Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS 11:F67-F71.
6. Benkirane, M., D. Y. Jin, R. F. Chun, R. A. Koup, and K. T. Jeang. 1997. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J. Biol. Chem. 272:30603-30606.
7. Biti, R., R. Ffrench, J. Young, B. Bennetts, G. Stewart, and T. Liang. 1997. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat. Med. 3:252-253.
8. Braciak, T. A., K. Bacon, Z. Xing, D. J. Torry, F. L. Graham, T. J. Schall, C. D. Richards, K. Croitoru, and J. Gauldie. 1996. Overexpression of RANTES using a recombinant adenovirus vector induces the tissue-directed recruitment of monocytes to the lung. J. Immunol. 157:5076-5084.
9. Chelli, M., and M. Alizon. 2001. Determinants of the trans-dominant negative effect of truncated forms of the CCR5 chemokine receptor. J. Biol. Chem. 276:46975-46982.
10. Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P. D. Ponath, L. Wu, C. R. Mackay, G. LaRosa, W. Newman, N. Gerard, C. Gerard, and J. Sodroski. 1996. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148.
11. Dean, M., M. Carrington, C. Winkler, G. A. Huttley, M. W. Smith, R. Allikmets, J. J. Goedert, S. P. Buchbinder, E. Vittinghoff, E. Gomperts, S. Donfield, D. Vlahov, R. Kaslow, A. Saah, C. Rinaldo, R. Detels, S. J. O'Brien, et al. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273:1856-1862.
12. (Comment, Science 273:1797-1798; erratum, Science 274:1069.)
13. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R. E. Sutton, C. M. Hill, C. B. Davis, S. C. Peiper, T. J. Schall, D. R. Littman, and N. R. Landau. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666.
14. (Comment, Nature 381:647-648.)
15. Doranz, B. J., J. Rucker, Y. Yi, R. J. Smyth, M. Samson, S. C. Peiper, M. Parmentier, R. G. Collman, and R. W. Doms. 1996. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85:1149-1158.
16. Dragic, T., V. Litwin, G. P. Allaway, S. R. Martin, Y. X. Huang, K. A. Nagashima, C. Cayanan, P. J. Maddon, R. A. Koup, J. P. Moore, and W. A. Paxton. 1996. HIV-1 entry into CD4(+) cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
17. Gorry, P. R., C. Zhang, S. Wu, K. Kunstman, E. Trachtenberg, J. Phair, S. Wolinsky, and D. Gabuzda. 2002. Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5D32 allele. Lancet 359:1832-1834.
18. Gray, L., M. J. Churchill, N. Keane, J. Sterjovski, A. M. Ellett, D. F. Purcell, P. Poumbourios, C. Kol, B. Wang, N. K. Saksena, S. L. Wesselingh, P. Price, M. French, D. Gabuzda, and P. R. Gorry. 2006. Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5Δ32 allele. J. Virol. 80:3684-3691.
19. Guignard, F., C. Combadiere, H. L. Tiffany, and P. M. Murphy. 1998. Gene organization and promoter function for CC chemokine receptor 5 (CCR5). J. Immunol. 160:985-992.
20. Hladik, F., H. Liu, E. Speelmon, D. Livingston-Rosanoff, S. Wilson, P. Sakchalathorn, Y. Hwangbo, B. Greene, T. Zhu, and M. J. McElrath. 2005. Combined effect of CCR5-Δ32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission. J. Virol. 79:11677-11684.
21. Kostrikis, L. G., Y. Huang, J. P. Moore, S. M. Wolinsky, L. Zhang, Y. Guo, L. Deutsch, J. Phair, A. U. Neumann, and D. D. Ho. 1998. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat. Med. 4:350-353.
22. Kozak, M. 2002. Emerging links between initiation of translation and human diseases. Mamm. Genome 13:401-410.
23. Kozak, M. 1996. Interpreting cDNA sequences: some insights from studies on translation. Mamm. Genome 7:563-574.
24. Kuipers, H., C. Workman, W. Dyer, A. Geczy, J. Sullivan, and R. Oelrichs. 1999. An HIV-1-infected individual homozygous for the CCR-5 delta32 allele and the SDF-1 3′ A allele. AIDS 13:433-434.
25. Liu, R., X. Zhao, T. A. Gurney, and N. R. Landau. 1998. Functional analysis of the proximal CCR5 promoter. AIDS Res. Hum. Retrovir. 14:1509-1519.
26. Mariani, R., S. Wong, L. C. Mulder, D. A. Wilkinson, A. L. Reinhart, G. LaRosa, R. Nibbs, T. R. O'Brien, N. L. Michael, R. I. Connor, M. Macdonald, M. Busch, R. A. Koup, and N. R. Landau. 1999. CCR2-64I polymorphism is not associated with altered CCR5 expression or coreceptor function. J. Virol. 73:2450-2459.
27. Martin, M. P., M. Dean, M. W. Smith, C. Winkler, B. Gerrard, N. L. Michael, B. Lee, R. W. Doms, J. Margolick, S. Buchbinder, J. J. Goedert, T. R. O'Brien, M. W. Hilgartner, D. Vlahov, S. J. O'Brien, and M. Carrington. 1998. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282:1907-1911.
28. McDermott, D. H., P. A. Zimmerman, F. Guignard, C. A. Kleeberger, S. F. Leitman, P. M. Murphy, et al. 1998. CCR5 promoter polymorphism and HIV-1 disease progression. Lancet 352:866-870.
29. Meyer, L., M. Magierowska, J. B. Hubert, C. Rouzioux, C. Deveau, F. Sanson, P. Debre, J. F. Delfraissy, I. Theodorou, et al. 1997. Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. AIDS 11:F73-F78.
30. Michael, N. L., J. A. Nelson, V. N. Kewal Ramani, G. Chang, S. J. O'Brien, J. R. Mascola, B. Volsky, M. Louder, G. C. White, II, D. R. Littman, R. Swanstrom, and T. R. O'Brien. 1998. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 Δ32. J. Virol. 72:6040-6047.
31. Mummidi, S., S. S. Ahuja, E. Gonzalez, S. A. Anderson, E. N. Santiago, K. T. Stephan, F. E. Craig, P. O'Connell, V. Tryon, R. A. Clark, M. J. Dolan, and S. K. Ahuja. 1998. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat. Med. 4:786-793.
32. Mummidi, S., S. S. Ahuja, B. L. McDaniel, and S. K. Ahuja. 1997. The human CC chemokine receptor 5 (CCR5) gene. Multiple transcripts with 5′-end heterogeneity, dual promoter usage, and evidence for polymorphisms within the regulatory regions and noncoding exons. J. Biol. Chem. 272:30662-30671.
33. Naif, H. M., A. L. Cunningham, M. Alali, S. Li, N. Nasr, M. M. Buhler, D. Schols, E. de Clercq, and G. Stewart. 2002. A human immunodeficiency virus type 1 isolate from an infected person homozygous for CCR5Δ32 exhibits dual tropism by infecting macrophages and MT2 cells via CXCR4. J. Virol. 76:3114-3124.
34. O'Brien, S. J., and J. P. Moore. 2000. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol. Rev. 177:99-111.
35. O'Brien, T. R., C. Winkler, M. Dean, J. A. Nelson, M. Carrington, N. L. Michael, and G. C. N. White. 1997. HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet 349:1219.
36. (Comment, Lancet 350:742.)
37. Sheppard, H. W., C. Celum, N. L. Michael, S. O'Brien, M. Dean, M. Carrington, D. Dondero, and S. P. Buchbinder. 2002. HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion. J. Acquir. Immune Defic. Syndr. 29:307-313.
38. Signori, E., C. Bagni, S. Papa, B. Primerano, M. Rinaldi, F. Amaldi, and V. M. Fazio. 2001. A somatic mutation in the 5′UTR of BRCA1 gene in sporadic breast cancer causes down-modulation of translation efficiency. Oncogene 20:4596-4600.
39. Theodorou, I., L. Meyer, M. Magierowska, C. Katlama, C. Rouzioux, et al. 1997. HIV-1 infection in an individual homozygous for CCR5 delta 32. Lancet 349:1219-1220.
40. (Comment, Lancet 350:742.)
41. Venkatesan, S., A. Petrovic, D. I. Van Ryk, M. Locati, D. Weissman, and P. M. Murphy. 2001. Reduced cell surface expression of CCR5 in CCR5{DELTA}32 heterozygotes is mediated by gene dosage, not by receptor sequestration. J. Biol. Chem. 16:16.
42. Zimmerman, P. A., A. Buckler-White, G. Alkhatib, T. Spalding, J. Kubofcik, C. Combadiere, D. Weissman, O. Cohen, A. Rubbert, G. Lam, M. Vaccarezza, P. E. Kennedy, V. Kumaraswami, J. V. Giorgi, R. Detels, J. Hunter, M. Chopek, E. A. Berger, A. S. Fauci, T. B. Nutman, and P. M. Murphy. 1997. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol. Med. 3:23-36.